R-CHOP has been the standard first-line treatment for DLBCL for over two decades, despite several attempts to improve on it with a variety of approaches.55 The FIRST-MIND study incorporates either tafasitamab alone or tafasitamab–lenalidomide alongside R-CHOP as a first-line therapy for DLBCL. This evidence concerns the gene DDIT3 and diffuse large B-cell lymphoma.